Predictive impact of previous coronary artery bypass grafting on mortality after MitraClip implantation for ischemic functional mitral regurgitation.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 10 10 2018
revised: 25 01 2019
accepted: 19 02 2019
pubmed: 16 3 2019
medline: 6 2 2020
entrez: 16 3 2019
Statut: ppublish

Résumé

Many candidates with ischaemic functional mitral regurgitation (FMR) have previously undergone coronary artery bypass grafting (CABG), in which transcatheter mitral valve repair can be reasonable for ameliorating the deteriorated hemodynamic and heart failure symptoms. We sought to elucidate the outcomes of MitraClip (MC) implantation in patients with symptomatic ischaemic FMR after CABG. We investigated clinical characteristics, outcomes and predictive impact of previous CABG on mortality in ischaemic FMR patients who underwent MC implantation from two high-volume centres in Germany. We enrolled 159 patients who previously underwent CABG. Compared with a reference group that did not previously undergo CABG (n = 182), the cohort consisted of more elderly patients (75.0, standard deviation [SD] 7.7 versus 72.9, SD 9.6 years, p = 0.028), more men (84% vs. 69%, p < 0.001), and reduced tricuspid annular plane systolic excursion (14.0, SD 4.0, vs. 16.6, SD 4.6 mm, p < 0.0001). The CABG group showed similar outcomes regarding procedural success (91% vs. 94%, p = 0.24) and 30-day mortality (5.0% vs. 6.0%, p = 0.68), but worse survival after MC implantation (log-rank p = 0.019, hazard ratio 1.56 [95% confidence interval (CI) 1.08-2.26]). After propensity score matching (n = 224), the hazard ratio was 1.18 [95%CI 0.76-1.84] without statistical significance (p = 0.46). Transcatheter mitral valve repair using the MC is a viable treatment option for patients with symptomatic ischaemic FMR after CABG. Although the baseline characteristics seemed to point to sick patients, CABG itself had only a modest impact on survival.

Sections du résumé

BACKGROUND
Many candidates with ischaemic functional mitral regurgitation (FMR) have previously undergone coronary artery bypass grafting (CABG), in which transcatheter mitral valve repair can be reasonable for ameliorating the deteriorated hemodynamic and heart failure symptoms. We sought to elucidate the outcomes of MitraClip (MC) implantation in patients with symptomatic ischaemic FMR after CABG.
METHODS
We investigated clinical characteristics, outcomes and predictive impact of previous CABG on mortality in ischaemic FMR patients who underwent MC implantation from two high-volume centres in Germany.
RESULTS
We enrolled 159 patients who previously underwent CABG. Compared with a reference group that did not previously undergo CABG (n = 182), the cohort consisted of more elderly patients (75.0, standard deviation [SD] 7.7 versus 72.9, SD 9.6 years, p = 0.028), more men (84% vs. 69%, p < 0.001), and reduced tricuspid annular plane systolic excursion (14.0, SD 4.0, vs. 16.6, SD 4.6 mm, p < 0.0001). The CABG group showed similar outcomes regarding procedural success (91% vs. 94%, p = 0.24) and 30-day mortality (5.0% vs. 6.0%, p = 0.68), but worse survival after MC implantation (log-rank p = 0.019, hazard ratio 1.56 [95% confidence interval (CI) 1.08-2.26]). After propensity score matching (n = 224), the hazard ratio was 1.18 [95%CI 0.76-1.84] without statistical significance (p = 0.46).
CONCLUSIONS
Transcatheter mitral valve repair using the MC is a viable treatment option for patients with symptomatic ischaemic FMR after CABG. Although the baseline characteristics seemed to point to sick patients, CABG itself had only a modest impact on survival.

Identifiants

pubmed: 30871803
pii: S0167-5273(18)35920-5
doi: 10.1016/j.ijcard.2019.02.045
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-26

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Mitsunobu Kitamura (M)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Hidehiro Kaneko (H)

Heart Center Brandenburg in Bernau/Berlin & Medical School Brandenburg (MHB), Bernau, Germany.

Michael Schlüter (M)

Asklepios Proresearch, Hamburg, Germany.

Dimitry Schewel (D)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Tobias Schmidt (T)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Hannes Alessandrini (H)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Felix Kreidel (F)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Maki Okamoto (M)

Heart Center Brandenburg in Bernau/Berlin & Medical School Brandenburg (MHB), Bernau, Germany.

Michael Neuss (M)

Heart Center Brandenburg in Bernau/Berlin & Medical School Brandenburg (MHB), Bernau, Germany.

Christian Butter (C)

Heart Center Brandenburg in Bernau/Berlin & Medical School Brandenburg (MHB), Bernau, Germany.

Karl-Heinz Kuck (KH)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany.

Christian Frerker (C)

Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany. Electronic address: christian.frerker@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH